Free Trial
NASDAQ:BIAF

bioAffinity Technologies Q1 2025 Earnings Report

bioAffinity Technologies logo
$0.24 0.00 (-0.08%)
Closing price 04:00 PM Eastern
Extended Trading
$0.25 +0.01 (+2.93%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

bioAffinity Technologies EPS Results

Actual EPS
-$0.16
Consensus EPS
-$0.16
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

bioAffinity Technologies Revenue Results

Actual Revenue
$1.85 million
Expected Revenue
$2.11 million
Beat/Miss
Missed by -$255.00 thousand
YoY Revenue Growth
N/A

bioAffinity Technologies Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Thursday, May 15, 2025
Conference Call Time
9:00AM ET

Upcoming Earnings

bioAffinity Technologies' Q3 2025 earnings is scheduled for Wednesday, November 12, 2025, with a conference call scheduled on Thursday, November 13, 2025 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

bioAffinity Technologies Earnings Headlines

bioAffinity Amends Warrant Floor Price in Recent Agreement
“Sell Nvidia before earnings”
Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has been chasing the AI giant, Eric says its biggest customers are now its biggest competitors — and that could spell trouble ahead. Instead, he’s urging investors to consider a little-known hardware company that’s already starting to take off. In fact, while Nvidia has slipped over the past 30 days, this “off-the-radar” stock is up 18% — and Eric believes the run is just beginning.tc pixel
bioAffinity Technologies Appoints New Board Members
See More bioAffinity Technologies Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like bioAffinity Technologies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on bioAffinity Technologies and other key companies, straight to your email.

About bioAffinity Technologies

bioAffinity Technologies (NASDAQ:BIAF), a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level. The company was incorporated in 2014 and is based in San Antonio, Texas.

View bioAffinity Technologies Profile

More Earnings Resources from MarketBeat